Metabolic Characterization of Patients With Dilated Cardiomyopathy a Prospective Case-control Study
The overall aim of the study is to explore the energy metabolism of the failing heart. Primary objective is to understand the differences in the energy metabolism in patients with DCM and heart failure compared to matched controls without heart failure. Secondary objectives, is to understand if optimal medical therapy, including sodium-gucose transporter 2 inhibitors (SGLT2i), alter the cardiac metabolism in DCM-patients. The investigators will also examine if changes in cardiac metabolism happens during exercise in patients with DCM. This will be done with invasive measurements of a range of energy substrate metabolites in the coronary sinus of the heart in patients with heart failure due to DCM and controls without heart failure respectively. A range of other clinical characteristics will also be examined to characterize patients and controls.
• Signed and dated the Informed Consent Form
• Male and female subjects ≥18 years of age
• Chronic Heart failure (HF) with LVEF ≤40%
• HF due to dilated cardiomyopathy (DCM)
• New York Heart Association (NYHA) class ≥2
• Treatment with basic optimal medical therapy.
• Clinical indication for invasive evaluation of heart failure
• Signed and dated Informed Consent Form
• Male and female subjects ≥18 years of age
• Clinical indication for electrophysiology examination